Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

102.70 -1.97 (-1.88%)
Streaming Delayed Price Updated: 12:23 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
70 71 Next >
US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People
The U.S. 
Via Benzinga
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Small-cap speculative biotech stocks regain interest with volatility. 
Via Talk Markets
BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British Startup
 
Via Benzinga
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
From BioNTech SE
Via GlobeNewswire
BioNTech Starts Dosing In Herpes Vaccine Candidate Study
 
Via Benzinga
Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly
Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients. 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy Right Now
These two pharmaceutical companies pay market-beating dividends to shareholders. 
Via The Motley Fool
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
From BioNTech SE
Via GlobeNewswire
Will Investors Notice Exciting Sign On BioNTech's Chart?
 
Via Benzinga
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
 
Via Benzinga
Why BioNTech Was a Sickly Stock This Week
The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks. 
Via The Motley Fool
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Three Pharma Stocks to Sell Before They Die
As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January. 
Via InvestorPlace
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
From BioNTech SE
Via GlobeNewswire
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
From BioNTech SE
Via GlobeNewswire
Update on First BioNTainer for African-based mRNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
From BioNTech SE
Via GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
 
Via Benzinga
Why Is Novavax (NVAX) Stock Plunging Today?
NVAX stock is down today on fundraising plans. Here's what investors should know about this once-promising Covid-19 vaccine player. 
Via InvestorPlace
Pfizer Expects $10-$15B From mRNA Vaccine Sales By 2030, Sees $17B Revenues Lost Due To Patent Expiry
At Pipeline Day, Pfizer Inc (NYSE: PFE) forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
 
Via Benzinga
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
From BioNTech SE
Via GlobeNewswire
FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old
 
Via Benzinga
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
From BioNTech SE
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.